Clinical Trials Logo

p53 Mutations clinical trials

View clinical trials related to p53 Mutations.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06088030 Recruiting - Pediatric Cancer Clinical Trials

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.

NCT ID: NCT04695223 Recruiting - Refractory Cancer Clinical Trials

Arsenic Trioxide for Structural p53 Mutations

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.